

## Hydroxychloroquine

S

### Acute generalised exanthematic pustulosis following off label treatment: 2 case reports

In a report, a woman and a man [*ages not stated*] were described, who developed acute generalised exanthematic pustulosis following off label treatment with hydroxychloroquine for COVID-19. The patients were diagnosed with COVID-19. They were hospitalised in Iran, and started receiving off label treatment with hydroxychloroquine [*routes and dosages not stated*]. Subsequently, they developed acute generalised exanthematic pustulosis due to hydroxychloroquine [*duration of treatment to reaction onset not stated, not all outcomes stated*].

Daneshpazhooh M, et al. COVID-19: The experience from Iran. *Clinics in Dermatology* 39: 23-32, No. 1, Jan 2021. Available from: URL: <http://doi.org/10.1016/j.clindermatol.2020.12.009>

803576083